SETD7 and prostate cancer: Moreover, SETD7 knockdown impairs ERα recruitment to its target genes in human breast cancer cells.29,89 AR also stimulates cell proliferation and anti-apoptotic responses, and it is the clinical biomarker of choice for prostate cancer diagnosis and treatment decisions.88,90 AR methylation at K630 by SETD7 enhances AR transcriptional activity.36,89 Thus, a potential role for SETD7 in the regulation of hormone-independent growth and endocrine resistance and its use as a cancer biomarker and/or as a therapeutic target should be explored.